Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

A. Laparra; M. Kfoury; S. Champiat; F. X. Danlos; P. Martin-Romano; A. Simonaggio; C. Baldini; P. Vuagnat; C. Mateus; A. L. Voisin; L. Albiges; B. Besse; C. Even; C. Robert; S. Laghouati; C. Massard; A. Marabelle; O. Lambotte; J. M. Michot

doi:10.1016/j.annonc.2021.04.006

Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

A. Laparra, M. Kfoury, S. Champiat, F. X. Danlos, P. Martin-Romano, A. Simonaggio, C. Baldini, P. Vuagnat, C. Mateus, A. L. Voisin, L. Albiges, B. Besse, C. Even, C. Robert, S. Laghouati, C. Massard, A. Marabelle, O. Lambotte, J. M. Michot

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

4 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	936-937
Nombre de pages	2
journal	Annals of Oncology
Volume	32
Numéro de publication	7
Les DOIs	https://doi.org/10.1016/j.annonc.2021.04.006
état	Publié - 1 juil. 2021

Accès au document

10.1016/j.annonc.2021.04.006

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Laparra, A., Kfoury, M., Champiat, S., Danlos, F. X., Martin-Romano, P., Simonaggio, A., Baldini, C., Vuagnat, P., Mateus, C., Voisin, A. L., Albiges, L., Besse, B., Even, C., Robert, C., Laghouati, S., Massard, C., Marabelle, A., Lambotte, O., & Michot, J. M. (2021). Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials? Annals of Oncology, 32(7), 936-937. https://doi.org/10.1016/j.annonc.2021.04.006

@article{854d5fbb08fc419a931450ec7f8ac426,

title = "Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?",

author = "A. Laparra and M. Kfoury and S. Champiat and Danlos, {F. X.} and P. Martin-Romano and A. Simonaggio and C. Baldini and P. Vuagnat and C. Mateus and Voisin, {A. L.} and L. Albiges and B. Besse and C. Even and C. Robert and S. Laghouati and C. Massard and A. Marabelle and O. Lambotte and Michot, {J. M.}",

note = "Funding Information: None declared. JMM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor; and reports non-financial support (drugs, equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.) from AstraZeneca, Roche, Novartis, Gilead, Celgene and Bristol-Myers Squibb. OL reports paid expert testimony and consultancy fees from BMS France, MSD and AstraZeneca; consultancy fees from Incyte; and expert testimony for Janssen. CM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor. AM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor. All other authors have declared no conflicts of interest.",

year = "2021",

month = jul,

day = "1",

doi = "10.1016/j.annonc.2021.04.006",

language = "English",

volume = "32",

pages = "936--937",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "7",

}

Laparra, A, Kfoury, M, Champiat, S, Danlos, FX, Martin-Romano, P, Simonaggio, A, Baldini, C, Vuagnat, P, Mateus, C, Voisin, AL, Albiges, L, Besse, B, Even, C, Robert, C, Laghouati, S, Massard, C, Marabelle, A, Lambotte, O & Michot, JM 2021, 'Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?', Annals of Oncology, VOL. 32, Numéro 7, p. 936-937. https://doi.org/10.1016/j.annonc.2021.04.006

TY - JOUR

T1 - Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies

T2 - a new surrogate marker for clinical trials?

AU - Laparra, A.

AU - Kfoury, M.

AU - Champiat, S.

AU - Danlos, F. X.

AU - Martin-Romano, P.

AU - Simonaggio, A.

AU - Baldini, C.

AU - Vuagnat, P.

AU - Mateus, C.

AU - Voisin, A. L.

AU - Albiges, L.

AU - Besse, B.

AU - Even, C.

AU - Robert, C.

AU - Laghouati, S.

AU - Massard, C.

AU - Marabelle, A.

AU - Lambotte, O.

AU - Michot, J. M.

N1 - Funding Information: None declared. JMM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor; and reports non-financial support (drugs, equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.) from AstraZeneca, Roche, Novartis, Gilead, Celgene and Bristol-Myers Squibb. OL reports paid expert testimony and consultancy fees from BMS France, MSD and AstraZeneca; consultancy fees from Incyte; and expert testimony for Janssen. CM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor. AM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor. All other authors have declared no conflicts of interest.

PY - 2021/7/1

Y1 - 2021/7/1

UR - http://www.scopus.com/inward/record.url?scp=85107902413&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.04.006

DO - 10.1016/j.annonc.2021.04.006

M3 - Letter

C2 - 33865965

AN - SCOPUS:85107902413

SN - 0923-7534

VL - 32

SP - 936

EP - 937

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -